newsfilter
← Latest News
Business Wire·

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Phase 3 NEAT clinical trial nearing 50% enrollment; company reiterates expectation of enrollment completion in second quarter of 2025 and topline results in fourth quarter of 2025 Quince Therapeutics, Inc.